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Abstract
Resistance of hypoxic solid tumor niches to chemotherapy and radiotherapy remains a major scientific challenge that calls
for conceptually new approaches. Here we exploit a hitherto unrecognized ability of sickled erythrocytes (SSRBCs) but not
normal RBCs (NLRBCs) to selectively target hypoxic tumor vascular microenviroment and induce diffuse vaso-occlusion.
Within minutes after injection SSRBCs, but not NLRBCs, home and adhere to hypoxic 4T1 tumor vasculature with
hemoglobin saturation levels at or below 10% that are distributed over 70% of the tumor space. The bound SSRBCs
thereupon form microaggregates that obstruct/occlude up to 88% of tumor microvessels. Importantly, SSRBCs, but not
normal RBCs, combined with exogenous prooxidant zinc protoporphyrin (ZnPP) induce a potent tumoricidal response via a
mutual potentiating mechanism. In a clonogenic tumor cell survival assay, SSRBC surrogate hemin, along with H2O2 and
ZnPP demonstrate a similar mutual potentiation and tumoricidal effect. In contrast to existing treatments directed only to
the hypoxic tumor cell, the present approach targets the hypoxic tumor vascular environment and induces injury to both
tumor microvessels and tumor cells using intrinsic SSRBC-derived oxidants and locally generated ROS. Thus, the SSRBC
appears to be a potent new tool for treatment of hypoxic solid tumors, which are notable for their resistance to existing
cancer treatments.
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Introduction
Hypoxic tumor cells are present in the vast majority of human
solid cancers and establish significant niches for therapeutic
resistance and tumor recurrence. Under hypoxic conditions within
tumors, evolutionarily conserved oxygen sensors initiate distress
pathways that lead to activation of hypoxia-inducible transcription
factors, proinflammatory and pro-angiogenic stimuli [1]–[3]. The
latter induce a disordered network of blood vessels, anastomotic
branches, fenestrations and shunts resulting in heterogeneous
blood perfusion, nutrient delivery, cyclic or chronic deoxygenation
and aerobic glycolysis [4]. In this microenvironment, tumors
exhibit impaired drug transport, treatment resistance and aggres-
sive malignant progression.
Therapeutic attempts to selectively target hypoxic tumor cells
have largely focused on bioreductive prodrugs that are activated
by enzymatic reduction under moderate to severe hypoxic
conditions. To date, these agents have not proven clinically useful
[5]. Tirapazamine, the earliest prototype of this group demon-
strated no survival benefit when added to standard chemotherapy
and was associated with dose limiting myelosuppression related to
activation of aerobic reductases in normal tissues [6]. Although the
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key vulnerabilities of hypoxic cells are not yet determined, a
second approach uses small molecule inhibitors targeting hypoxia-
inducible factor 1 (HIF1), the unfolded protein response (UPR)
and mTOR pathways [5]. Both bioreductive and molecularly
targeted agents share the challenge of drug penetration through
poorly perfused hypoxic tissue [7],[8]. The bioreductive agents
must further deal with cumulative toxicity of their DNA-reactive
cytotoxins when used together with standard chemotherapeutics
[5]. Finally because of the heterogeneity in hypoxia between
tumours of the same type, both groups require in vivo diagnostics
to accurately measure hypoxia in order to select patients who can
benefit most from these treatments [9]. In view of these barriers,
conceptually new strategies and agents are needed. In one such
approach that differs fundamentally from those directed to
hypoxic tumor cells, we herein provide sickle erythrocytes
(SSRBCs) to target the hypoxic tumor vascular microenviroment
and induce a tumoricidal response using intrinsic SSRBC oxidants
and locally generated ROS. Importantly, this approach has little
effect on normal vasculature and lacks cumulative toxicity with
other cytotoxics suggesting that it may possess a broader
therapeutic index than agents that selectively target hypoxic
tumor cells alone.
In sickle cell disease, a monogenic mutation in the b-chain of
hemoglobin wherein the sixth amino acid in the b-globin chain is
changed from glutamic acid to valine, induces hemoglobin
polymerization and changes in erythrocyte morphology during
hemoglobin desaturation [10]. Disturbances resulting from this
mutation include impaired microvascular blood flow [11], episodic
vasoocclusion [12], ischemia-reperfusion injury [13], and endo-
thelial cell activation [14],[15]. Tissue hypoxia and deoxygenation
of SS hemoglobin occur frequently in sickle cell disease,
particularly in venules, where blood velocity is reduced
[11],[16]. Hypoxia, oxidative stress and proinflammatory cyto-
kines also upregulate several vascular adhesion receptors [17]–
[24]. In response to hypoxia, transgenic sickle mice show
pronounced vascular inflammation compared with normal mice,
leading to reduced blood flow and transient venular stasis
[24],[25]. In the course of painful sickle cell crisis, activated
SSRBCs adhere to adhesive ligands on the upregulated vascular
endothelium, recruit leukocytes and platelets leading to microves-
sel occlusion. SSRBCs entrapped in this process undergo
autohemolysis generating excessive reactive oxygen species and
autooxidized heme iron that results in severe tissue injury [26].
In a parallel to painful sickle cell crisis, the microvasculature of
most solid tumors is upregulated to express several vascular
adhesion molecules in response to cyclic hypoxia within the tumor
[2] and proinflammatory cytokines generated by tumor cells
[22],[24],[27]–[30].
These findings provided a conceptual basis for a seminal report
which precisely identified a central role for SSRBCs in targeting
the upregulated/hypoxic tumor vasculature, inducing vaso-occlu-
sion/autohemolysis and generating intrinsic/locally-derived oxi-
dants leading to endothelial injury and a tumoricidal response
[31]. Subsequently, SSRBCs were imaged in tumors or identified
in tumor microvessels at autopsy but there were no reported
therapeutic applications [32–34]. Here, we examine the original
concept and demonstrate novel properties of SSRBCs in
selectively targeting the hypoxic vascular microenvironment of
solid tumors, inducing diffuse tumor vascular occlusion and
potentiating the tumoricidal effectiveness of exogenous pro-
oxidants both in vivo and in vitro.
Results
4T1 mammary carcinoma is neovascularized, hypoxic and
expresses several adhesion molecules and heme
oxygenase
Initially, we studied the 4T1 carcinoma implanted in the dorsal
skin fold window chambers 8 days after tumor implantation for
evidence of neovascularization hypoxia, adhesion molecule and
heme oxygenase expression. In Figure 1 A,C, eight-day old 4T1
tumors exhibit a dense, disordered vascular network with acutely
branching capillaries and anastomotic channels. At this point, the
4T1 tumor vascular microenvironment is markedly hypoxic,
evidenced by hemoglobin saturation levels at or below 10% that
are distributed over 70% of the tumor space (Figure 1B,D). In
addition, tumor microvessels within 4T1 tumors exhibit expression
of adhesion ligands PCAM-1, VCAM-1, laminin a5 and av
integrins (Figure 2A–D). We also note increased expression of
heme oxygenase (HO-1) in 4T1 tumors compared to syngeneic
liver cells (Figure S1). Heme oxygenase protects cells against the
cytotoxic effect of heme and related oxidation products and is
relevant because heme is known to be released by hemolysis
during SSRBC-induced vaso-occlusion as described below. Based
on these studies, intravital microscopy studies using SSRBCs and
NLRBCs described below were conducted on 8-day old 4T1
tumors which are neovascularized, hypoxic and express several
adhesion molecules along with heme oxygenase.
SS RBCs but not normal RBCs accumulate preferentially
in tumors and occlude tumor microvessels in vivo
Using intravital microscopy with tumors implanted in dorsal
skin fold window chambers, we sought to characterize the
behavior of intravenously administered SSRBCs and NLRBCs
in 8 day old hypoxic and neovascularized 4T1 carcinomas. Within
5 minutes after infusion, fluorescently labeled SSRBCs adhered to
a large number of core and peripheral tumor microvessels
(Figure 3A, Movie S1/legend). By thirty minutes, SSRBC
adherence to microvessel walls increased resulting in formation
of microaggregates that occluded both curved and straight
segments of tumor microvessels (Figure 4A,C,E; S1/legend).
Blood stasis evident at this point (Movie S1) was further
substantiated by the identification of individual labeled cells on
still images (Figure 4A,C,E). In the same time period, NLRBCs
displayed minimal adhesion or vaso-occlusion in tumor vessels
(Figure 3B; Figure 4BDF, Movie S1/legend) and neither NLRBCs
nor SSRBCs showed appreciable adhesion or vaso-occlusion in
adjacent normal host subdermal vascular endothelium
(Figure 3C,D, Movie S1/legend).
Quantitation of SSRBC and NLRBC tumor uptake and
vaso-occlusion
To quantitate the SSRBC uptake and vaso-occlusion in tumors,
compared to NLRBCs, we analyzed still images from intravital
microscopic video 30 minutes after NLRBC or SSRBC infusion
into mice bearing 4T1 tumors. Mice infused with fluorescently-
labeled SSRBCs showed substantially greater fluorescence in
tumor vessels compared to NLRBCs (p,0.005) and increased
uptake in tumor vessels compared to adjacent normal subdermal
vessels (p,0.008) (Figure 3G). Similarly, tumor tissues showed a
38-fold increase in RFP fluorescence of SSRBCs trapped in
tumors compared to l NLRBCs (p = 0.00001) (Figure 3E,F,H).
With respect to vaso-occlusion, fluorescently-labeled SSRBCs
occluded 8862.20%(SEM) of tumor vessels compared to
1.7461.37%(SEM) for NLRBCs (p,0.00001) and
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4.462.12%(SEM) for SSRBCs in adjacent host normal subdermal
vessels (p,0.00001) (Figure 4G).
Biodistribution of normal RBCs and SS RBCs in normal
tissues and tumors
We wished to determine whether the selective uptake of
SSRBCs but not NLRBCs in tumors also occurred in normal
organs. We therefore analyzed sections of organs and tumors
harvested within 24 hours after infusion of RFP labeled SSRBCs
or NLRBCs into 4T1 carcinoma for the presence of RFP-labeled
SSRBCs or NLRBCs. Whereas uptake of SSRBCs in 4T1 tumors
was significantly greater compared to NLRBCs (p = 0.0014), there
were no significant differences in NLRBC versus SSRBC uptake
in spleen, lungs or kidney (Figure 5A). Sections of tumor tissue
from mice receiving SSRBCs examined at this time showed areas
of cytoplasmic eosinophilia with capillary engorgement consistent
with acute ischemia not seen in tumors of mice injected with
NLRBCs (Figure 5E). Corresponding sections of spleen, lungs and
kidneys from mice receiving SSRBCs or NLRBCs were devoid of
inflammation, infarction or necrosis, indicating that SSRBCs did
not induce acute injury to normal organ (Figure S2). These data
indicate that SSRBC deposition in 4T1 tumor microvasculature
significantly exceeds that of NLRBCs but not in other normal
organs and that SSRBC uptake in tumors is accompanied
histologically by acute ischemic changes but no significant
pathology in normal organs.
SSRBCs but not NLRBCs plus a pro-oxidant regimen
induce a tumoricidal effect against 4T1 carcinoma in vivo
Studies in sickle cell patients have shown that SSRBCs involved
in postcapillary occlusion can release SSRBC-derived heme,
hemichrome and ROS causing oxidative tissue damage [35]–
[41]. We therefore determined whether SSRBCs could induce a
tumoricidal response when the tumor cells are rendered suscep-
tible to oxidative stress with exogenous pro-oxidants. For this
purpose, we deployed two potent pro-oxidative regimens, zinc
protoporphyrin (ZnPP) (a competitive inhibitor of heme oxygen-
ase) alone or together with doxorubicin (ZnPP-D). Both regimens
were shown previously to efficiently promote cytotoxicity of tumor
cells exposed to oxidative stress in vitro in an NADH-dependent
manner [42],[43]. Groups of 10 mice with established 4T1 tumors
were treated with one or three SSRBC infusions plus ZnPP or
ZnPP-D (see Table S1 for protocol). This resulted in a dramatic
delay in tumor growth compared to the PBS control group
(p,0.0001) (Figure 6A). Notably, the group receiving three
SSRBC infusions showed a quadrupling of growth delay
compared to PBS control. In contrast, tumor bearing mice
receiving SSRBCs1x or 3x or NLRBCs1x or 3x, ZnPP alone,
Doxil alone or combinations of NLRBCs3x with ZnPP,
NLRBCs1x or 3x with Doxil or ZnPP-D induced no growth
delay compared to the PBS control (Figure 6B). Since SSRBCs1x
or 3x show potent anti-tumor effects when used in combination
but are ineffective by themselves, SSRBCs together with ZnPP or
Figure 1. Eight day old 4T1 carcinoma is vascularized and hypoxic. Intravital microscopy of two eight day old 4T1 tumors implanted in the
dorsal skin window chamber viewed with light microscopy shows diffuse tumor microvascularity (panels A, C). Corresponding hyperspectral imaging
of the same tumors exhibits hemoglobin saturations #10% over a 70% of the tumor surfaces (B,D). Magnification 56.
doi:10.1371/journal.pone.0052543.g001
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ZnPP-D appear to exhibit a mutual potentiation. Mice displayed
no acute toxicity of SSRBC1x or 3x combined with ZnPP or
ZnPP-D and there were no significant differences in weights
compared to the PBS control group (p = 0.485). H&E sections
from mice treated with SSRBC + ZnPP-D showed more diffuse
tumor necrosis than PBS controls. Spleens of mice treated with
SSRBCs3x + ZnPP-D displayed scattered hemosiderin deposits
not present in untreated control tissues. However, liver, kidney,
spleen and brain, including the hippocampus, cortex, cerebellum
and Purkinje fibers, from SSRBC-treated and PBS controls were
unremarkable and notably devoid of SSRBC vascular aggregates,
inflammation, infarction and necrosis. Thus, treatment with
SSRBC3x + ZnPP-D did not induce histologically demonstrable
toxicity in normal host organs.
Sickle cell oxidants induce 4T1 cell death in the presence
of pro-oxidants in vitro
We sought to understand the mechanism of the mutual
potentiation between SSRBCs and ZnPP in the tumoricidal effect
noted in vivo. In the course of vascular adhesion, entrapped
SSRBCs generate pro-oxidant membranes along with oxidized
hemichrome and activated endothelial cells produce hydrogen
peroxide (H2O2) [36],[38],[41]. We reasoned that tumor cells
deprived of oxidant protection by heme oxygenase inhibition
would be susceptible to apoptosis. To test this hypothesis, we used
a clonogenic tumor cell survival model in vitro in which we
exposed 4T1 cells to heme oxygenase inhibition (ZnPP) [44],
hemin [protoporphyrin IX containing ferric iron (heme b)] and
H2O2 alone and in various combinations (see Figure S2 for
protocol). Incubation of 4T1 tumor cells with hemin, H2O2 or
ZnPP alone resulted in no significant tumor killing (p.0.5).
Likewise, using hemin together with H2O2 or ZnPP did not
enhance the tumor cell killing (p.0.05) (Figure 7). In contrast,
treating 4T1 cells with i) hemin alone or combined with ZnPP for
2 hrs followed by ZnPP and H2O2 for 2 hrs or, ii) ZnPP for
2 hours followed by hemin and H2O2 for 2 hrs resulted in
significantly increased 4T1 tumor cell killing compared to each
agent alone (p,0.0002) or any two of these agents used
simultaneously (p,0.0001) (Figure 7). Since only the three agent
regimen (ZnPP, hemin and H2O2) used simultaneously or
sequentially produced a significant tumoricidal effect whereas
the individual agents were ineffective, these data are concordant
with the mutual potentiation of SSRBCs and ZnPP in the
tumoricidal response described above in vivo in the 4T1 tumor
model.
Discussion
Resistance of hypoxic solid tumor niches to chemotherapy and
radiotherapy remains a major scientific challenge that invites
conceptually new approaches. Here we exploit the previously
unrecognized ability of the sickled erythrocyte (SSRBC), but not
NLRBCs, to selectively target hypoxic microvessels of solid tumors
and induce diffuse tumor vascular occlusion. Importantly,
SSRBCs, but not normal RBCs, also induce a potent tumoricidal
response via a mutual potentiation of exogenous pro-oxidants
ZnPP or ZnPP-D. A clonogenic tumor cell survival model
confirms this mutual potentiation and demonstrates a key obligate
role for SSRBC-derived heme and H2O2 in potentiating the
tumoricidal effect of ZnPP. In addition to SSRBC’s remarkable
tumor targeting ability, this is the first report that harnesses the
SSRBC for anti-tumor therapy.
In contrast to pharmaceutical treatment directed only to the
hypoxic tumor cell, the present approach targets the hypoxic
tumor vascular microenviroment and induces injury to hypoxic
tumor microvessels and tumor cells using intrinsic SSRBC
oxidants and locally generated ROS. Data in Figures 3 and 4
and their legends plus the Movie S1 demonstrate that the initial
events in the tumoricidal process consist of rapid adherence of
SSRBCs but not NLRBC to tumor vasculature, formation of
microraggregates leading to diffuse tumor microvessel occlusion.
The SSRBC adherence to tumor microvessels could not be
ascribed to non-specific RBC trapping since NLRBCs rarely
adhered to tumor vessels. Likewise, it could not be attributed to
asymmetric distribution of SSRBCs cells and NLRBCs in the host,
since NLRBCs and SSRBCs sequester in normal organs to a
similar degree.
Concurrent with SSRBC localization, adherence and occlusion
of tumor microvessels, our data further demonstrate the presence
hypoxia in the 4T1 tumor microenvironment. Hyperspectral
imaging indicates that 70% or the 4T1 tumor microvessels exhibit
a hemoglobin saturation between 0–10% which corresponds to
pO2 values ,10% mm Hg in the oxygen-hemoglobin dissociation
curve [45],[46]. This degree of tumor hypoxia [8],[47] could
prime the tumor vasculature for adherence/vaso-occlusion by
SSRBCs by stimulating tumor cell synthesis of proangiogenic/pro-
inflammatory proteins such as VEGF and TNFa [1],[2],[24],[26].
The latter upregulates several tumor vascular adhesion molecules
capable of capturing activated SSRBCs [23],[24],[27]–[30].
Figure 2 demonstrates that several such vascular adhesion ligands
are expressed in tumor microvessels. As in painful sickle cell crisis,
the inflammatory/procoagulant condtions at the site of SSRBC-
inuduced tumor vaso-occlusion could also promote platelet
activation and leukocyte recruitment leading to accelerated
vascular injury [26].
Figure 2. Expression of adhesion molecules on 4T1 tumor
vascular endothelium. Frozen sections of 4T1 tumors stained with
antibodies against various adhesion molecules shows significant
endothelial expression of PECAM-1 (A), ICAM-4 (B), laminin a5 (C). av
integrin (D). Secondary antibodies alone used as negative controls to
stain the same tumor sections are shown in the inset of each panel.
Magnification 406.
doi:10.1371/journal.pone.0052543.g002
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Our proposed mechanism of the tumoricidal effect in this
system, shown schematically in Figure 8, implicates SSRBCs-
induced tumor vaso-occlusion in hypoxic tumor vessels as the
central event in both tumor vascular endothelial cell and tumor
cell injury. We hypothesize that SSRBCs entrapped in the vaso-
occlusive process undergo autohemolysis and release intrinsic
hemichrome, hemoglobin S and ROS. These powerful cellular
toxins are capable of inducing tumor endothelial cell and tumor
cell injury [35]–[40]. SSRBC hemichrome, for instance, sponta-
neously generates twice as much superoxide, peroxide/hydroxyl
radicals as NLRBCs [35],[38] and hemoglobin S is rapidly
converted to methemoglobin which forms highly lipophilic heme-
nitrosyl complexes that intercalate and oxidize cell membranes
[48]. Tumor endothelial cells activated by SSRBCs contribute to
the process by generating hydrogen peroxide, leading to endo-
thelial membrane injury (peroxidation) and diapedesis of inflam-
matory monocytes into the tumor parenchyma [19],[41].
We further surmised that the effectiveness of these SSRBC/
endothelial cell-derived oxidants is enhanced when the tumor and
endothelial cells are exposed to ZnPP, a metalloporphyrin that
competitively inhibits the degradation of heme by heme oxygenase
[49]. The latter, a 32-kD microsomal membrane enzyme is
overexpressed in the 4T1 tumor and a broad array of tumor cell
types [49]. Indeed, these studies show that SSRBC infusion
combined with ZnPP exhibited a unique mutual potentiation in
tumor killing in vivo. This novel effect was mimicked in our
clonogenic tumor survival model in vitro wherein hemin and
H2O2., surrogates for SSRBC-derived hemichrome and endothe-
lial cell H2O2 respectively, efficiently potentiated the death of
ZnPP-treated 4T1 tumor cells.
The accelerated tumor growth noted after a single SSRBC
infusion was reversible after the addition of ZnPP, a potent
inhibitor of HO-1. This effect may be ascribed to SSRBC-induced
vaso-occlusion in the tumor resulting in increased tumor hypoxia
and release of SSRBC-derived heme. Both heme and hypoxia
activate HIF-1a in tumor cells which, in turn, stimulates synthesis
of HO-1 [50]. The latter is a powerful stimulant of tumor
angiogenesis and promotes tumor growth [49]. Since the addition
of ZnPP to SSRBCs abrogated the accelerated tumor growth and
promoted statistically significant growth delay, HO-1 may be
pivotal in the accelerated tumor growth process induced by
SSRBCs alone. In clinical translation, it would appear that
Figure 3. SSRBCs but not NLRBCs accumulate in tumor microvessels within 30 minutes after injection. Intravital microscopy of the
vasculature of 8-day old 4T1 tumors implanted in the dorsal skin window chamber within 30 minutes after infusion of mice with SSRBCs (A, C, E) or
NLRBCs (B,D,F) shows the accumulation of SSRBCs but not NLRBCs in the tumor blood vessels and tumor parenchyma (A,B,E,F). At the same time,
SSRBC uptake is observed in the tumor vessels, there is minimal uptake in the adjacent subdermal blood vessels (C). There is also minimal uptake of
NLRBCs in adjacent subdermal blood vessels (D) (Magnification 56). Thirty minutes after infusion, the uptake of fluorescently-labeled SSRBCs (n = 5)
or NLRBCs (n = 5) in tumor vessels (G) and tumor parenchyma (H) is quantitated in still video images (fluorescence intensity (FI) at Magnification 206).
SSRBCs (n = 6) show significantly greater mean FI in tumor vessels and parenchyma (G and H respectively) compared to subdermal skin vessels or
NLRBCs (n = 3) (p = 0.00001 for FI of SSRBCs in tumor vessels and tumor parenchyma vs. respective controls in both G and H). Abbreviations in legend:
AS: adjacent subdermal skin vessels.
doi:10.1371/journal.pone.0052543.g003
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SSRBCs should be administered with caution and preferably
together with prooxidant agents to avoid promoting tumor
growth.
Importantly, mice infused with SS RBCs and ZnPP or ZnPP-D
showed no significant organ toxicity, and body weights were stable
throughout the study. Only the tumor showed extensive necrosis,
whereas spleen, liver, brain, lungs and kidneys from the treated
mice were devoid of infarction, inflammation and necrosis. Thus,
it appears that the cytotoxic activity of SSRBC/ZnPP-D is
selective for the tumor but not normal tissues. As a source of
SSRBCs for clinical use, nucleated sickle progenitor cells
(phenotypic and functional sickle cells) can be readily expanded/
differentiated in vitro. Moreover, nucleated SS progenitors can
also be transduced with virtually any tumoricidal transgene. Thus,
the SSRBC appears to be a potent and versatile new tool for




All animal experiments were approved by the Duke University
ACUC. Female athymic homozygous nude mice (nu-/nu-),
between 8–12 weeks of age weighing 19–26 grams, obtained from
Charles River Laboratories (Wilmington, MA) or Harlan Labo-
ratories (Indianapolis, IN) were used for all experiments. The
animals were housed 5 animals per cage in a 12 h light-dark cycle
with water, food ad libitum. All infusions were performed using the
tail vein.
Cell lines, virus and reagents
The 4T1 murine mammary carcinoma, a thioguanine and
doxorubicin resistant tumor [51,52], were cultured with DMEM
supplemented with 10% (v/v) fetal bovine serum (and 1% (v/v)
antibiotics-antimycotics as previously described [53]. All cell lines
were monitored routinely and found to be free of mycoplasma
infection. Fresh solutions of hemin (Sigma) in DMSO and Zn (II)
Protoporphyrin IX (Frontier Scientific) in 50% DMSO-50%
0.1 M NaOH was made for each experiment. H2O2 was
purchased from (Sigma-Aldrich, St. Louis, MO).
Western blotting analysis of HO-1 expression
For immunoblotting, proteins were extracted from snap frozen
mouse tumor, kidney, and liver tissues. Tissues were homogenized
and dissolved in the cold RIPA buffer (Pierce, Rockford, IL). Cell
debris was separated by centrifuging twice at 10,000 g for 10 min
at 4uC. Whole protein concentration was measured by Bradford
assay (Bio-Rad Laboratories, Hercules, CA). Each Protein
preparation (100 mg) was electrophoresed in 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins
were transferred to PVDF (polyvinylidene fluoride) membrane and
blocked for 1 hour with 5% non-fat dried milk in TBST (20 mM
Tris-HCl, 150 mM NaCl, and 0.1% Tween 20, pH 7.5).
Figure 4. SSRBCs but not NLRBCs form microaggregates and occlude tumor microvessels. Thirty minutes after infusion of SSRBCs or
NLRBCs into mice bearing eight day old 4T1 tumors, diffuse tumor vaso-occlusion is evident in mice injected with SSRBCs (A,C,E) but not NLRBCs
(B,D,F). (Magnification 106was used in panels 1–4 and 206 in panels 5 and 6). Arrows indicate SSRBC adhesion to vascular walls, microaggregate
formation and partial or complete microvessel occlusion. The mice injected with SSRBCs (n = 5) showed a significantly greater percentage of occluded
tumor vessels compared to NLRBCs (n = 5) or adjacent subdermal skin vessels (G) (p = 0.00001 for SSRBCs in tumor vessels vs. NLRBCs or adjacent
subdermal skin vessels). Magnification 206 was used for quantitation of tumor microvessel occlusion. Abbreviations in legend: Adj. skin: adjacent
subdermal skin vessels.
doi:10.1371/journal.pone.0052543.g004
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Membranes were incubated overnight with 1:500 diluted anti-
mouse HO-1 antibodies (Assay Designs, Ann Arbor, Michigan),
washed three times with TBST and incubated with 1:1000 diluted
horseradish peroxidase (HRP)-conjugated anti-mouse IgG anti-
body for 1 hour at room temperature followed by washing with
TBST. The blot was immunodetected with enhanced chemilumi-
nescence (ECL) detection system (Perkin Elmer, Waltham,
Massachusetts). For a loading control, 50 mg of protein was
loaded in 10% SDS-PAGE and blotted with 1:2000 diluted anti-
mouse b-actin antibody (Sigma-Aldrich).
Figure 5. SSRBCs accumulate to a significantly greater degree in tumors compared to NLRBCs. RFP-labeled SSRBCs (n = 4) or NLRBCs
(n = 2) were injected into mice bearing eight day old 4T1 tumors. Twenty four hours later tumors and organs were collected and RFP fluorescence
quantitated on sections of tumors and organs. The uptake of SSRBCs in tumors is significantly greater than NLRBCs (p = 0.0014) (A, B, D). In contrast,
the uptake of SSRBCs and NLRBCs is not significantly different in the spleen, lungs and kidneys (p.0.05) (A) (Magnification 56). H&E tumor sections
from SSRBC-treated mouse show focal areas of cytoplasmic eosinophilia consistent with ischemia (E) not present in tumors treated with NLRBCs (C)
(Magnification 206). Abbreviations in legend: negTumor, negLung, negSpleen, negKidney mean mice injected with NLRBCs or SSRBCs without RFP
label.
doi:10.1371/journal.pone.0052543.g005
Figure 6. SSRBCs but not NLRBCs combined with prooxidants ZnPP and ZnPP-D induce a tumoricidal response in 4T1 bearing mice.
The fraction of mice with tumors ,56 the pretreatment volumes versus time is shown (n = 10 for each treatment group). All three groups treated
with SSRBCs combined with ZnPP or ZnPP-D show significant tumor growth delay compared to PBS controls. In the adjacent Table, a control
experiment shows that tumor bearing animals receiving SSRBCs 16or 36 alone, NLRBC 16 or 36 alone, NLRBCs 16 or 36with ZnPP or ZnPP-D,
ZnPP alone or Doxil + ZnPP exhibited no significant tumor growth delay versus the PBS control. * indicates that mice receiving SSRBC16 alone
displayed significantly accelerated tumor growth compared to the PBS control.
doi:10.1371/journal.pone.0052543.g006
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Immunohistochemical localization of adhesion molecules
in tumor microvessels
Frozen tumor tissues were sectioned at 10 micron thickness and
were kept at 280uC until the immunohistochemistry was
performed (n = 5). Before staining, frozen tissue sections were
air-dried for 30 minutes and fixed for 10 minutes in cold acetone.
Tissues were air-dried again for 30 minutes and incubated with
phosphate-buffered saline (PBS) for 5 minutes. After 30-minute
blocking with 10% serum, tissues were incubated overnight at 4uC
with primary antibodies, CD31 (PECAM-1), CD106 (VCAM-1),
CD51 (Integrin av) all from BD Pharmingen and laminin a5, a
kind gift from Dr. Jeffrey H. Miner, Washington University, St.
Louis. Slides were then washed three times in PBS for 5 min
followed by the incubation with the appropriate secondary
antibody (Jackson Immuno-Research, West Grove, PA) for
30 min at room temperature. Again slides were washed three
times in PBS for 5 min followed by incubation with ABC-Elite
(Vector Laboratories, Burlingame, CA) for 30 min at room
temperature. Reaction was localized by using 3.39-diaminobenzi-
dine tetrachloride (DAB) working solution (Laboratory Vision,
Fremont, CA). Finally, the slides were counterstained with Harris
haematoxylin (Fisher Scientific, Pittsburgh, PA) and mounted with
coverslips. For image analysis the slides were systematically
scanned with a light microscope (Zeiss Axioskop 2 plus,
Oberkochen, Germany) and digital images were acquired from
each slide using 56, 106, and 406 objectives using the software
(Axiovision 3.1).
Collection, preparation and treatment of human RBCs
NLRBCs were obtained from normal healthy adults or SSRBCs
from homozygous SS patients with approval by the Institutional
Review Board and Ethics Committees of Duke University and
informed consent was obtained from each donor. All participants
provided their written informed consent to participate in this study
which was documented by two witnesses. Fresh blood samples
from patients homozygous for hemoglobin S and from normal
controls were collected into citrate tubes. RBCs were allowed to
separate from the buffy coat containing leukocytes and platelet-
rich plasma by gravity at 4uC for at least 2 h. Plasma and buffy
coat were removed by aspiration and RBCs were washed four
times in sterile PBS with 1.26 mM Ca2+, 0.9 mM Mg2+ (pH 7.4).
Packed RBCs were analyzed for leukocyte and platelet contam-
ination using an Automated Hematology Analyzer Sysmex K-
1000 (Sysmex, Co., Cobe, Japan). Packed RBCs were fluorescently
labeled with DiI (Molecular Probes, Eugene, OR) for in vivo uptake
studies as previously described [54],[55]. Dil has no effect on RBC
suspension viscosity or RBC survival in the circulation [54]. Cells
were then washed three times with 5 ml PBS with Ca2+ and Mg2+.
Window chamber surgery and murine mammary
carcinoma implantation
This procedure has been described previously [56]. General
anesthesia was induced by intraperitoneal (IP) injection of
100 mg/kg of ketamine (Abbott Laboratory, Chicago, IL) and
10 mg/kg of xylazine (Bayer, Shawnee Mission, KS). A double-
sided titanium frame window chamber was surgically implanted
into the dorsal skin fold under sterile conditions with aseptic
technique. Surgery involved carefully removing the epidermal and
dermal layers of one side of a dorsal skin fold, exposing the blood
vessels of the subcutaneous tissue adjacent to the striated muscles
of the opposing skin fold. The two sides of the chamber were
secured to the skin using stainless steel screws and sutures, followed
by injection of 16104 4T1 tumor cells into the exposed fascia. A
glass window was placed in the chamber to cover the exposed
Figure 7. Tumoricidal effect of the combination of hemin, H2O2 and ZnPP in a clonogenic tumor survival model. Three agent regimens
consisting of pre-treating 4T1 cells with i) hemin alone or combined with ZnPP for 2 hrs followed by the combination of ZnPP and H2O2 for 2 hrs or,
ii) ZnPP for 2 hours followed by the combination of hemin and H2O2 for 2 hours induced significant tumor cell death compared to each agent
individually (**p,0.0002) and any two of these agents used simultaneously ({p,0.0001). Clonogenic survival is shown as a mean of three
independent experiments with standard error (SE) indicated. See Table S2 for protocol used in these studies.
doi:10.1371/journal.pone.0052543.g007
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tissue, and was secured to the chamber with a snap ring. Animals
were kept in a specialized environmental chamber at 32–34uC and
50% humidity until in vivo studies were performed 8 days post-
surgery.
Intravital microscopy and visualization of RBC trafficking
The set up for window chamber visualization was identical to
that described above. Labeled human NLRBCs or SSRBCs
(300 mL; hematocrit 50% in PBS with Ca2+ and Mg2+) were
infused through the tail vein and blood flow dynamics were
observed in both tumor neovasculature and subdermal vessels for
at least 30 minutes, using LD Achroplan 20X/0.40 Korr and
Fluar 5X/0.25 objectives (Zeiss). Microcirculatory events and cell
adhesion were simultaneously recorded using a Trinitron Color
video monitor (model PVM-1353 MD, Sony) and JVC videocas-
sette recorder (model BR-S3784, VCR King, Durham, NC)
connected to a digital video camera C2400 (Hamamatsu
Photonics K.K., Japan). Blood vessels were also viewed under
fluorescence-illumination using a 100-W mercury arc lamp and
56 and 206magnifications.
Hemoglobin saturation determinations in the 4T1 tumor
microvasculature using hyperspectral imaging information was
described previously [57]. A Zeiss Axioskop 2 microscope (Carl
Zeiss, Inc., Thornwood, NY) served as the imaging platform.
Images were acquired with a CCD camera (DVC Company,
Austin, TX), and bandlimited optical filtering for hyperspectral
imaging was accomplished with a C-mounted liquid crystal
tunable filter (CRI, Inc., Woburn, MA). Image processing was
performed using Matlab software (The Mathworks, Inc., Natick,
MA). Microvessel-based pixel counts of vessels in window chamber
tumors were quantitated as a fraction of microvessels pixels with
hemoglobin saturations of 10% or less over the total number of
micropixels in the tumor as described [57].
Quantification of vaso-occlusion was performed by examining
videotapes using 206 magnification. Multiple segments of tumor
and adjacent normal subdermal microvessels were examined
30 minutes following SS RBC and normal RBC infusions. Vessels
were counted as occluded by considering labeled cells attached to
the vessel walls and immobile for at least 10 seconds with no
observable blood flow. The percentage of vessels occluded by SS
or normal RBCs was calculated by division of the number of
occluded vessels by the total number of vessels in the field that
contained visible blood flow at baseline.
Histology
The animals used in window chamber experiments were
sacrificed 30 minutes post-injection of Dil-labeled RBCs. Tumors
and organs were collected and snap frozen in OCT media. Forty
micron sections were cut from four standardized locations in each
organ mounted and examined via inverted fluorescence micros-
copy. Three random fields were imaged for each section of each
organ. RBC fluorescence intensity for each field was quantified
Figure 8. Schematic depiction of proposed pathophysiology of tumor killing induced by SSRBCs and the HO-1 inhibitor ZnPP. The
hypoxic and acidic tumor milieu activates HIF1a, which, in turn, stimulates VEGF and HO-1 expression and the production of TNFa. TNFa upregulates
several adhesion molecules on tumor endothelium, including several endothelial cognate adhesion ligands for the major adhesion receptors
expressed on SSRBCs. Deformable non-sickled SS RBCs adhere to the activated endothelium of the tumor vasculature, along with leukocytes to form
microaggregates leading to tumor vascular obstruction/occlusion. Entrapped SSRBCs release SS hemoglobin which is converted rapidly to
methemoglobin and cleaved to liberate free heme. Hydrophobic and lipophilic heme and/or heme-nitrosyl complexes permeate tumor and
endothelial cell membranes where they catalytically oxidize lipids, proteins and DNA causing cell death. In the presence of ZnPP, a competitive
inhibitor of HO-1, intracellular heme and oxidative products such as reactive oxygen and nitrogen species (ROS and RNS) are free to exert their potent
oxidative function leading to tumor and endothelial cell death.
doi:10.1371/journal.pone.0052543.g008
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using Adobe Photoshop CS2 software (Adobe Systems Inc., San
Jose, CA). Five determinations of pixel intensity were obtained for
each field and averaged for the three fields to obtain mean
fluorescence intensity. The mean fluorescence values were
averaged among groups of animals for statistical analysis. In
tumor therapy studies, tumors, organs and brain from hippocam-
pus, cortex, cerebellum and Purkinje fibers were collected in 4%
paraformaldehyde or 10% formalin and stained using hematoxylin
and eosin and Prussian blue.
Tumor therapy studies
All procedures were approved by the Duke University
Institutional Animal Care and Use Committees or the Animal
Use Committees in compliance with the Guide for the Care and
Use of Laboratory Animals. For the studies in mice bearing 4T1
carcinoma, tumor volume and body weight were measured every 2
days, and volumes were calculated as p/6*length2*width. The
treatment endpoint was 56 treatment volume or 1500 mm3,
whichever was reached first. Zinc (II) protoporphyrin IX (Zn-PP;
Frontier Scientific) was dissolved in a solution of saline and N,N
dimethylformamide (DMF) at a 95/5 volume ratio to a
concentration of 0.1 mg/ml prior to i.p. injection. Lyophilized
Doxorubicin (DOX; Bedford Laboratories) was hydrated with
saline (2 mg/ml) prior to i.v. administration. Study groups
consisted of 10 mice per cohort. Treatments were started when
the tumors were at a median volume of 72 mm3 (57–90 mm3
interquartile range). SSRBCs were infused iv in 150–200 ml,
hematocrit 50%, Zn-PP, 0.5 mg/kg, was injected i.p. and
Doxorubicin, 5 mg/kg, was administered. i.v. on a schedule
shown in Table S1. Tumors were measured twice a week with
standard calipers and mice were monitored for toxicity. Mice were
euthanized if toxicity was evident or tumor burden exceeded
1500 mm3.
Biodistribution studies
RFP-labeled SSRBCs or NLRBCs (300 mL; hematocrit 50% in
PBS with Ca2+ and Mg2+) were infused through the tail vein into
atyhmic nude mice bearing eight day old 4T1 tumors. Twenty
four hours later tumors and organs were collected. RFP
fluorescence was quantitated as described below at magnification
56 using Adobe Photoshop CS2 software (Adobe Systems Inc.,
San Jose, CA). Five to ten determinations of pixel intensity were
obtained for each field and averaged for the three fields to obtain
mean fluorescence intensity. The mean fluorescence values for
tumors and organs in each group were used for statistical analysis.
Clonogenic survival assays
4T1 were plated in 6-well plates at two different densities (100
and 300 cells per well) in 3 ml of media and allowed to attach for
24 hr at 37uC. For the individual treatments, cells were treated for
2 hr with DMSO (vehicle), hemin (100 mM), H2O2 (100 mM), or
the Zn (II) protoporphyrin IX (ZnPP) (10 mM). For the combina-
tion treatments, cells were treated with the indicated agents for
2 hr, which were then removed and followed by treatment with
the other agents for an additional 2 hr. After the last treatment,
the media containing drugs was removed and the cells incubated
in fresh media at 5% CO2 and 37uC for 7–10 days. After
incubation, cells were fixed with 10% methanol-10% acetic acid
and stained with a 0.4% crystal violet solution. Colonies with .50
cells were counted using a ColCounter (Oxford Optronix). Plating
efficiencies were determined for each treatment and normalized to
controls. The data shown in Figure 7 is the mean of 3 independent
experiments. The protocol for this study is shown in Table S2.
Statistics
All data analysis was performed using GraphPad Prism version
4.03 for Windows (GraphPad Software, San Diego California
USA). Kaplan-Meier analysis was used to evaluate treatment
efficacy for 4T1 carcinoma studies. Statistical comparison were
performed with Kruskal-Wallis or log rank test. For multiple
comparisons in the 4T1 study, p,0.01 was considered the threshold
for significance. In clonogenic tumor survival studies, the plating
efficiency was 0.4 for 4T1 cells and 4T1 cell survival was normalized
to the DMSO control. Two way ANOVA was used to compare
surviving fraction of cells among independent treatment groups with
treatment and experiment as categorical independent factors.
Specific contrasts by F test under linear models were used to assess
the treatment difference between groups with type I error adjusted
to 0.01. Window chamber/histology data, starting tumor volume
size, maximum weight change were analyzed using either student
T-test or Kruskal-Wallis for multiple group comparisons.
Supporting Information
Figure S1 Expression of heme oxygenase-1 in tumor and
normal tissues. Western blots of protein extracted from 4T1
tumor, normal liver and kidney, stained for heme oxygenase-1 (HO-
1). Increased expression of HO-1 in the tumor was observed
compared to the kidney and liver tissues. For a loading control,
proteins were blotted with an anti-mouse b-actin antibody.
(TIF)
Figure S2 H&E sections of organs from 4T1 bearing
mice 24 hours post RBC infusion. H&E sections of lung,
spleen and kidney from mice infused with SSRBCs (n = 5) or
NLRBCs (n = 3) 24 hours post SSRBC or NLRBC infusion were
unremarkable and notably devoid of inflammation, infarction or
necrosis. (Magnification106)
(TIF)
Movie S1 Intravital microscopy of the skin window of
mice using 8 day old 4T1 carcinoma infused with
SSRBCs or NLRBCs. SSRBC-1: Five minutes after infusion
of SSRBCs, the SSRBCs are adherent to vascular walls and
deposited in relatively avascular core (circular, dark area at top)
and periphery of the tumor microvasculature. Microcapillary
obstruction is evident along with reduced velocity of SSRBCs as
they transit through partially obstructed vessels. At 20 minutes,
SSRBC microaggregates have formed in the vessels several of
which have progressed to frank vaso-occlusion (Magnifications
106). At 30 minutes, extensive aggregate formation and vaso-
occlusion is noted along with retrograde blood flow in a patent
capillary segment within surrounding occluded microvessels
(Magnifications 206). NLRBCs depicted 30 minutes after infusion
into mice with 8 day old 4T1 carcinoma exhibit minimal
adherence to tumor microvessels with no evidence of vaso-
occlusion (Magnifications 106).
(MOV)
Table S1 Schedule of treatments.
(TIF)
Table S2 Clonogenic tumor model protocol.
(TIF)
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